Clinical Data CatalYm begins phase 2b trial of visugromab in second-line liver cancer treatment PharmaTimesStudy expands development of the antibody into hepatocellular carcinomaClinical DataOncologyRead full story pharminent April 7, 2026 (Last updated: April 7, 2026) PharmaTimes Study expands development of the antibody into hepatocellular carcinoma Clinical DataOncologyRead full story Post navigation Previous: In the face of tariffs, FDA-approved drug manufacturing deals are shifting to EuropeNext: FDA Seeks Expanded Authority To Regulate Postapproval Manufacturing Changes Related Stories Clinical Data Novartis hit as Lp(a) drug fails cardio outcomes trial pharminent September 7, 2026 Clinical Data Major trial of Roche Alzheimer’s drug kicks off in Europe pharminent September 7, 2026 Clinical Data AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study pharminent September 4, 2026